Suppressive effect of dipyridamole on platelet-mediated epithelial-mesenchymal transition in breast cancer

Epithelial-to-mesenchymal transition (EMT) is a key process implicated in cancer metastasis. Platelets are recognized as important initiators of EMT, with interactions between platelets and tumor cells contributing not only to the formation of tumor-associated thrombi but also the promotion of cancer metastasis. Dipyridamole, an antiplatelet agent commonly used in the treatment of cardiovascular and cerebrovascular diseases has recently been shown to enhance the efficacy of certain antitumor drugs. However, the standalone antitumor effects of dipyridamole, either in vitro or in vivo, have not yet been well-documented. This study aimed to investigate the impact of dipyridamole on platelet-mediated EMT in breast cancer through in vivo and in vitro models. The findings may uncover a novel antitumor mechanism of dipyridamole and suggest a potential new therapeutic approach for breast cancer.